All In Biotech

Free tool

FAERS Monitor: Renografin-76

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 010040 or its brand name (Renografin-76, Diatrizoate Meglumine, Diatrizoate Sodium). Reports on generic versions are filed under their own applications.

Reports

158

Serious

144

91% of reports

Hospitalization

122

Death reported

96

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use85
  • drug ineffective78
  • nausea75
  • pain73
  • rash72
  • confusional state71
  • dyspnoea71
  • treatment failure71
  • wound71
  • therapeutic product effect decreased70
  • pericarditis69
  • psoriatic arthropathy69
  • type 2 diabetes mellitus69
  • drug hypersensitivity68
  • pemphigus68

Reports by year received

View as table
YearReports
20041
20054
20061
20072
20084
20093
20102
20112
20121
20131
20152
20171
20183
20196
20208
20213
20224
20238
202420
202559
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,001 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pemphigusSignal68728.0608.048,411
pericarditisSignal69549.0459.637,076
woundSignal71339.0285.123,562
type 2 diabetes mellitusSignal69273.4229.018,447
psoriatic arthropathySignal69226.7189.815,282
therapeutic product effect decreasedSignal70208.4174.914,248
treatment failureSignal71114.296.17,877
confusional stateSignal7158.549.23,985
drug hypersensitivitySignal6846.839.13,029
rashSignal7222.018.51,452
dyspnoeaSignal7116.714.11,061
painSignal7315.813.41,029
off label useSignal8512.911.2963
nauseaSignal7512.610.7821
drug ineffectiveSignal787.96.7492

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.